Infectious Diseases Search
Infectious Diseases Infectious Diseases
tinea%20unguium
TINEA UNGUIUM
Onychomycosis is a fungal infection of the nail bed, nail plate or both. It is caused by dermatophytes, non-dermatophyte molds and yeast.
Tinea unguium or dermatophytic onychomycosis is a dermatophyte infection of the nail more commonly affecting the toenails than the fingernails.
It is usually asymptomatic and patients first consult for cosmetic reasons.
It is suspected if there are changes in the 3rd or 5th toenail, involvement of the 1st and 5th toenails on the same foot and unilateral nail changes.
Drug Information

Indication: Relief of external thrush symptoms.

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Tinea pedis, cruris, corporis & versicolor; cutaneous candidiasis.

Indication: Acute or recurrent genital & vag candidiasis, candidal balanitis, dermatomycosis including tinea pedis, ti...

Indication: Cryptococcosis ie, cryptococcal meningitis & infections of other sites (eg, pulmonary, cutaneous). Mainten...

Indication: Fungal skin infections including candidiasis, tinea & pityriasis versicolor.

Indication: Management of superficial candidiasis & fungal skin infections eg, mucocutaneous candidiasis, dermatophyto...

Indication: Cryptococcosis. Systemic, mucosal & vag candidiasis. Prevention of fungal infection in patient w/ malignan...

1  /  8
1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Single-tablet combo regimen fares well in HIV treatment
Audrey Abella, 06 Aug 2019
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.